Regulators in the United States and Europe have accepted applications for a new treatment aimed at adults living with a rare and debilitating autoimmune muscle disorder. The U.S. Food and Drug Administration and the European Medicines Agency are now reviewing cemdisiran for patients with generalized myasthenia gravis who test positive for anti-acetylcholine receptor antibodies, a subgroup that accounts for the majority of cases.
The submissions rely on data from the Phase 3 NIMBLE trial, one of the largest global studies ever conducted in generalized myasthenia gravis. In the trial, patients received cemdisiran as a subcutaneous injection every 12 weeks, while continuing standard immunosuppressant therapy at their doctor’s discretion. Full results were published simultaneously in The Lancet and presented at the American Academy of Neurology Annual Meeting in April 2026. A regulatory filing in Japan is planned for early 2027.
Myasthenia gravis is a chronic autoimmune disease in which abnormal antibodies attack the connection between nerves and muscles, leading to severe and sometimes life-threatening weakness. In the generalized form, the condition affects muscles throughout the body, causing extreme fatigue and difficulty with facial expression, speech, swallowing, and mobility. Worldwide, an estimated 150 to 200 people per million have the disorder, and about 85,000 people in the United States are affected. Many patients continue to struggle with existing treatments that only manage symptoms, require long-term immunosuppressants, or lose effectiveness over time.
What the Regulatory Decisions Mean for Patients
The FDA has granted Priority Review for the New Drug Application, with a target action date in November 2026, following the use of a Priority Review Voucher. A decision from the European Commission is expected in the second half of 2027. If approved, cemdisiran would offer a new option for patients who have not achieved adequate control with current therapies, delivered as an injection only four times a year.
For the thousands of people living with generalized myasthenia gravis, these regulatory reviews represent a step toward a treatment that could reduce the burden of frequent infusions and help stabilize muscle function over time. Patients and clinicians alike are watching closely as the November 2026 FDA deadline approaches, hopeful that a new chapter in managing this challenging condition may soon begin.